Studies

Solide tumoren, CLDN1+, fase 1, ALE.P02 ADC

Solide tumoren, CLDN1+, fase 1, ALE.P03

Solide tumoren, HER2-mutatie/amplificatie, fase 1 populatie, zongertinib

Solide tumoren, HER2 positief, fase 1, click-cleavable beeldvorming

Niet-kleincellig longcarcinoom, MET mutatie, fase 1, MET kinase inhibitor

Hepatocellulair carcinoom, fase 1, holmium-166

Solide tumoren, fase 1, CD137/PD-L1 bispecifiek antilichaam

mCRPC, fase 1/2, GSK5471713

Solide tumoren, fase 1 populatie, patritumab deruxtecan

Solide tumoren, fase 1, infinatamab deruxtexan

mCRPC, fase 1, ifinatamab deruxtecan

Solide tumoren, fase 1, T-cell engager, anti-nectine-4

Solide tumoren, fase 1, BI 3810944

mCRPC, fase 1, Lu-PSMA-617

PDAC, G12V KRAS mutatie, fase 1, TCR-T celtherapie